Morgan Stanley analyst Erin Wright raised the firm’s price target on Labcorp (LH) to $270 from $260 and keeps an Overweight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group. Calling 2025 the “Year of the Labs,” the firm says it expects volume should remain strong via healthy utilization trends continuing into 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LH:
- Labcorp launches H5 bird flu test in U.S.
- Labcorp price target raised to $271 from $262 at BofA
- Labcorp assumed with a Buy at Jefferies
- Labcorp Announces New CFO Amid Leadership Transition
- Labcorp CFO Glenn Eisenberg to retire, Julia Wang to succeed
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.